Rhythm AI Ltd

Rhythm AI Ltd focuses on developing advanced medical technologies to enhance the treatment of atrial fibrillation through innovative data analysis systems. Rhythm AI Ltd specializes in innovative medical technology, particularly the STAR Apollo Mapping System designed to improve atrial fibrillation treatment. Founded by Malcolm Finlay, the company is headquartered in London, UK, and raised GBP 2. 15 million in Seed funding on 30 August 2019, led by Rinkelberg Capital, valuing the company at GBP 6.

29 million post-money. Rhythm AI specializes in the development of advanced medical technologies, with its flagship product being the STAR Apollo Mapping System. This system enhances atrial fibrillation (AF) treatment by using real-time data analysis from electrophysiology systems. Utilizing sophisticated AI algorithms, it identifies arrhythmia patterns and potential drivers of AF, enabling highly personalized treatment plans for physicians.

Target customers include hospitals and electrophysiologists in the United States, where this innovative system is actively marketed. Rhythm AI's business model centers on B2B transactions, primarily through direct sales of the STAR Apollo Mapping System to healthcare facilities specializing in electrophysiology. Revenue is generated from these sales and ongoing service agreements to integrate the technology into existing workflows. The company also engages in partnerships with hospitals requiring staff training and support services for their operations.

Following the Seed funding round in September 2019, Rhythm AI plans to leverage the GBP 2. 15 million raised to support the development and launch of new products aimed at enhancing atrial fibrillation treatment. The company intends to expand its presence in the US market and explore opportunities in other regions. Plans include introducing innovative features to the STAR Apollo Mapping System, with a strategic focus on positioning itself as a comprehensive solution for healthcare providers in electrophysiology.